Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Guidelines recommend biomarker testing and biomarker-informed therapies in patients with metastatic non-small cell cancer (mNSCLC); however, the use remains suboptimal.
Methods: To understand contemporary testing and treatment patterns, retrospective data from 42,037 patients with mNSCLC in a nationwide electronic health record-derived deidentified database from January 2011 to April 2023 were used to quantify testing rates, test positivity, and use of biomarker-informed therapies, stratified by key demographics to identify potential disparities. Multivariable logistic regression was conducted to include patient characteristics associated with the receipt of biomarker testing and subsequent biomarker-informed therapies.
Results: A total of 34,510 patients (82.1%) received ≥one biomarker test(s). Biomarker testing and use of biomarker-informed therapies increased for all studied biomarkers (, , , PD-L1, , , ) over time, with highest rates observed in 2023: (88.7% and 79.5%, respectively) and (87.7% and 84.3%, respectively). In multivariate logistic regression, patient sex, race, Eastern Cooperative Oncology Group at baseline, insurance type, smoking status at baseline, and histology were all significantly associated with odds of receiving biomarker testing. Covariates statistically associated with receipt of biomarker-informed therapy varied by biomarker without a clear pattern of association. Although the use of biomarker testing and biomarker-informed therapies has increased in recent years, gaps and potential disparities remain.
Conclusion: Analysis of contemporary trends in biomarker testing and use of targeted therapies in mNSCLC in the United States highlight improvements in recent years. However, these rates remain suboptimal in specific strata of the patient population, including differences in racial groups and insurance groups, indicating further work is needed to bridge remaining gaps.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/PO-24-00449 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: In Armenia, a lower-middle-income country, cancer causes 21% of all deaths, with over half of cases diagnosed at advanced stages. Without universal health insurance, patients rely on out-of-pocket payments or black-market channels for costly immunotherapies, underscoring the need for real-world data to inform equitable policy reforms.
Methods: We conducted a multicenter, retrospective cohort study of patients who received at least one dose of an immune checkpoint inhibitor (ICI) between January 2017 and December 2023 across six Armenian oncology centers.
Intracellular lymphocyte protein biomarkers for early radiological triage in the human population.
PLoS One
September 2025
Center for Radiological Research, Columbia University Irving Medical Center, New York, New York, United States of America.
In the event of a large-scale radiological or nuclear emergency, a rapid, high-throughput screening tool will be essential for efficient triage of potentially exposed individuals, optimizing scarce medical resources and ensuring timely care. The objective of this work was to characterize the effects of age and sex on two intracellular lymphocyte protein biomarkers, BAX and p53, for early radiation exposure classification in the human population, using an imaging flow cytometry-based platform for rapid biomarker quantification in whole blood samples. Peripheral blood samples from male and female donors, across three adult age groups (young adult, middle-aged, senior) and a juvenile cohort, were X-irradiated (0-5 Gy), and biomarker expression was quantified at two- and three-days post-exposure.
View Article and Find Full Text PDFICTUSCOG: Poststroke cognitive impairment following nondisabling stroke: Study protocol of a spanish multicentre prospective cohort study.
PLoS One
September 2025
Department of Neurology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Background: Stroke is a leading cause of death and disability globally, with frequent cognitive sequelae affecting up to 60% of stroke survivors. Despite the high prevalence of post-stroke cognitive impairment (PSCI), early detection remains underemphasized in clinical practice, with limited focus on broader neuropsychological and affective symptoms. Stroke elevates dementia risk and may act as a trigger for progressive neurodegenerative diseases.
View Article and Find Full Text PDFThe SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors.
PLoS One
September 2025
Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
Background: Current aftercare in breast cancer survivors aims to detect local recurrences or contralateral disease, while the detection of distant metastases has not been a central focus due to a lack of evidence supporting an effect on overall survival. However, the data underpinning these guidelines are mainly from trials of the 1980s/1990s and have not been updated to reflect the significant advancements in diagnostic and therapeutic options that have emerged over the past 40 years. In this trial, the aim is to test whether a liquid biopsy-based detection of (oligo-) metastatic disease at an early pre-symptomatic stage followed by timely treatment can impact overall survival compared to current standard aftercare.
View Article and Find Full Text PDFUntangling the nets - a roadmap to standardized sampling and analysis of exhaled volatile organic compounds powered by medicine.
Am J Physiol Lung Cell Mol Physiol
September 2025
Division of Immunology, Immunity to Infection & Respiratory Medicine, University of Manchester, United Kingdom.
Biomarkers based on volatile organic compounds (VOCs) measured in human breath have been investigated in a wide range of diseases. However, the excitement surrounding such biomarkers has not yet translated to the discovery of any that are ready for clinical implementation. A lack of standardisation in sampling and analysis has been identified as a key obstacle to the validation of potential biomarkers in in multi-centre studies.
View Article and Find Full Text PDF